Affimed Introduces ROCK™ Platform for Tailored Immune Cell Engagers

On May 4, 2018, Posted by , In News, By , , With Comments Off on Affimed Introduces ROCK™ Platform for Tailored Immune Cell Engagers

Affimed N.V., a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced the official launch of its Redirected Optimized Cell Killing (ROCK™) platform. Based on the company’s long-standing expertise in drug development and protein engineering, the ROCK™ platform enables the generation of both NK…